Announced Fri, 7 Aug · 16:56 IST
Q1 FY27 results: revenue up 105% YoY; board forfeits 7.8 lakh warrants
Revenue Growth 20pctPat Growth 25pctNegative Operating CashflowResults View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.1%1-day move
₹17.99
prior close
₹18.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.5+2.5+2.5+2.7-0.1-6.6-2.7-6.6-2.7-2.8-12.0-18.8——
Up moveDown movePending
AI summary
Venmax Drugs reported Q1 FY27 revenue of Rs 247.94 lakh, up 105% YoY from Rs 121.03 lakh. PAT rose to Rs 11.66 lakh versus Rs 3.74 lakh. EPS at Rs 0.10. Board also approved forfeiture of 7,80,001 partly paid warrants worth Rs 39 lakh due to non-payment by 5 holders. Auditor gave an unmodified limited review.
Likely market impact
Strong revenue and profit growth year-on-year, but negative operating cash flow and warrant forfeiture flag weak investor follow-through.